Ribociclib
Kisqali · CDK4/6 inhibitor
Creatinine rise; QT prolongation.
Ibrance · Palbo
CDK4/6 inhibitor · approved 2015 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A CDK4/6 inhibitor that nudges creatinine up without truly injuring the kidney.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
A reversible rise in serum creatinine is common, but true structural kidney injury is uncommon. CDK4/6 inhibitors block the proximal-tubule transporters that secrete creatinine, producing a 'pseudo-AKI' picture. In a single-center palbociclib cohort 16% (8 of 50) met creatinine-based AKI criteria (Ly, PMID 39648753); the 17.5% often quoted is the whole mixed CDK4/6-inhibitor cohort of 234 patients, not the palbociclib arm. Where cystatin C was available, 73% of those events proved to be pseudo-AKI rather than a true GFR decline.Source: Ly et al. (PMID 39648753) — palbociclib-specific: 16% (8/50) creatinine-based AKI. Class-wide context: Buijs et al., Br J Cancer 2025 (PMID 39930149), 17.5% of 234 CDK4/6i-treated patients; pseudo-AKI 73% (16/22).
Creatinine typically rises within the first 1-2 cycles (median onset roughly 30-35 days), then plateaus and reverses after dose hold or discontinuation.
Distilled from: “Often within the first 1-2 cycles (median onset roughly 30-35 days); creatinine plateaus and reverses after dose hold or discontinuation.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Class effect: predominant renal signal is pseudo-AKI (creatinine rise from OCT2/MATE inhibition without a real GFR decline); true AKI (acute tubular injury, interstitial nephritis) is rare PMID 41385991 (opens PubMed in a new tab)
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Hypokalemia/hyponatremia reported but uncommon relative to the near-universal creatinine change PMID 41385991 (opens PubMed in a new tab)
Tap a signature to trace where it strikes the nephron.
Representative incidence
Pseudo-AKI strikes: Proximal Tubule.
Pseudo-AKI
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Selectively inhibits cyclin-dependent kinases 4 and 6, blocking retinoblastoma protein (Rb) phosphorylation and arresting the cell cycle at the G1/S checkpoint. Combined with endocrine therapy for HR-positive, HER2-negative early-stage and advanced breast cancer.
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Quoted verbatim from this agent's current FDA label (Jul 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dose adjustment is required in patients with mild, moderate, or severe renal impairment (CrCl >15 mL/min). Based on a pharmacokinetic trial in subjects with varying degrees of renal function, the total palbociclib exposure (AUC INF ) increased by 39%, 42%, and 31% with mild (60 mL/min ≤ CrCl <90 mL/min), moderate (30 mL/min ≤ CrCl <60 mL/min), and severe (CrCl <30 mL/min) renal impairment, respectively, relative to subjects with normal renal function. Peak palbociclib exposure (C max ) increased by 17%, 12%, and 15% for mild, moderate, and severe renal impairment, respectively, relative to subjects with normal renal function. The pharmacokinetics of palbociclib have not been studied in patients requiring hemodialysis [see Clinical Pharmacology (12.3) ] .
Kidney rows of the label's dosage tables
From the Ibrance label (Jul 2026) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 95,562 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
10,701 of 95,562 reports
Reported with hospitalization
14,535 of 95,562 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 21 of the 95,562 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Palbociclib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Kisqali · CDK4/6 inhibitor
Creatinine rise; QT prolongation.
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Bosulif · BCR-ABL TKI
Reversible eGFR decline.
Zykadia · ALK TKI
GI-driven prerenal AKI.
Koselugo · MEK inhibitor
Creatinine rise in neurofibromatosis.
Verzenio · CDK4/6 inhibitor
Benign creatinine rise via tubular secretion block.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.